SGLT2 inhibitors not only lower blood glucose levels but also have been shown to cause significant reductions in the risks of major adverse cardiovascular events (MACE)in patients with T2DM and established cardiovascular disease (CVD) [30]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.